Shenzhen Neptunus Bioengineering Co., Ltd. (SHE:000078)
1.560
+0.030 (1.96%)
Jun 11, 2026, 9:50 AM CST
SHE:000078 Revenue
Shenzhen Neptunus Bioengineering had revenue of 5.95B CNY in the quarter ending March 31, 2026, a decrease of -19.39%. This brings the company's revenue in the last twelve months to 25.24B, down -14.75% year-over-year. In the year 2025, Shenzhen Neptunus Bioengineering had annual revenue of 26.67B, down -12.04%.
Revenue (ttm)
25.24B
Revenue Growth
-14.75%
P/S Ratio
0.16
Revenue / Employee
3.75M
Employees
6,734
Market Cap
4.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.67B | -3.65B | -12.04% |
| Dec 31, 2024 | 30.32B | -6.10B | -16.75% |
| Dec 31, 2023 | 36.42B | -1.42B | -3.74% |
| Jan 1, 2023 | 37.83B | -3.22B | -7.84% |
| Jan 1, 2022 | 41.05B | 1.03B | 2.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.35B |
| Zhejiang Starry Pharmaceutical | 2.47B |
| Yabao Pharmaceutical Group | 2.20B |
| Hunan Fangsheng Pharmaceutical | 1.79B |
| Fuan Pharmaceutical (Group) | 1.68B |
| Tianjin Lisheng Pharmaceutical | 1.35B |
| Teyi Pharmaceutical Group Co.,Ltd | 839.27M |
| Beijing Science Sun Pharmaceutical | 402.62M |